Sector News

Sigma-Aldrich acquires Duolink product portfolio from Olink Bioscience

October 30, 2015
Life sciences

Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology company, today announced that it has signed an agreement to acquire the Duolink® product portfolio from Olink Bioscience.

The acquisition includes intellectual property, sales, marketing and manufacturing assets.

The newly acquired product line is designed for researchers studying biological pathways and seeking improved sensitivity to uncover disease biomarkers. Since 2013, Sigma-Aldrich has distributed Duolink reagents, along with pre-validated antibody pairs for proximity ligation assays (in situ PLA®).

“We are excited about the acquisition of the Duolink product portfolio. Duolink is valuable to our customers and complements the rest of Sigma-Aldrich’s Protein Biology portfolio,” said Amanda Halford, Vice President, Academic Research at Sigma-Aldrich. “Owning the Duolink technology will provide Sigma-Aldrich with opportunities to develop new products, as well as advance our existing technologies.”

Duolink Technology, based on PLA technology, enables researchers to visualize low levels of proteins, protein modifications and individual protein interactions directly in fixed cells and tissue samples without the need for overexpression. This technology can significantly enhance the rigor and reproducibility of scientific experiments, aided by dual recognition of antibody pairs.

“Duolink has been a very important product in the history and development of Olink, and we feel that with this acquisition by Sigma-Aldrich, it will be in very good hands and continue to be a great success,” said Jon Heimer, CEO of Olink Bioscience. “We will now focus our resources on further developing our Proseek® Multiplex product line for human protein biomarker research, as well as expanding our global presence by establishing local commercial organizations in Europe and North America, and continuing to develop new innovative tools for the scientific community.”

“Duolink technology is transforming the way scientists study biological pathways. It allows interactions between proteins at the endogenous levels to now be visualized, providing researchers with reproducible data they can see,” said Halford. “The acquisition of Duolink allows Sigma-Aldrich to provide comprehensive solutions for enabling experimental reproducibility, with continued reliability in supply and quality.”

Source: Sigma-Aldrich

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”